No surprises in there,
Many eyes will be on MSB and its FDA GvHD approval, If it does, that makes RGS' intellectual property stupidly cheap (as opposed to sillily cheap). Expect a raft of halo effect buying in the stem cell sector. Sadly mkts are that predictable. The FDA approval is not alas.....
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.020(4.76%) |
Mkt cap ! $4.832M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.0¢ | 40.0¢ | $2.792K | 6.87K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7117 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 1910 | 1 |
View Market Depth
| Last trade - 14.13pm 29/07/2024 (20 minute delay) ? |
| CMB (ASX) Chart |